Contents

Foreword by Dr Hamaguchi *xiii*
Foreword by Dr Noyori *xv*
Preface *xvii*

1 Control of DNA Packaging by Block Catiomers for Systemic Gene Delivery System *1*
Kensuke Osada
1.1 Introduction *1*
1.2 Packaging of pDNA by Block Catiomers *2*
1.2.1 Rod-Shaped Packaging of pDNA *3*
1.2.2 Rod Shape or Globular Shape *5*
1.3 Polyplex Micelles as a Systemic Gene Delivery System *6*
1.3.1 Stable Encapsulation of pDNA Within Polyplex Micelles for Systemic Delivery *6*
1.3.2 Polyplex Micelles for Efficient Cellular Entry *9*
1.3.3 Polyplex Micelles for Safe Endosome Escape *11*
1.3.4 Polyplex Micelles for Nuclear Translocation *13*
1.3.5 Polyplex Micelles for Efficient Transcription *13*
1.4 Design Criteria of Block Catiomers Toward Systemic Gene Therapy *14*
1.5 Rod Shape or Toroid Shape *17*
1.6 Summary *18*
References *18*

2 Manipulation of Molecular Architecture with DNA *25*
Akinori Kuzuya
2.1 Introduction *25*
2.2 Molecular Structure of DNA *25*
2.3 Immobile DNA Junctions *26*
2.4 Topologically Unique DNA Molecules *28*
2.5 DNA Tiles and Their Assemblies *28*
2.6 DNA Origami *30*
2.7 DNA Origami as a Molecular Peg Board *32*
2.8 Molecular Machines Made of DNA Origami *33*
2.9 DNA Origami Pinching Devices *33*

2.10 Novel Design Principles *35*
2.11 DNA-PAINT: An Application of DNA Devices *36*
2.12 Prospects *36*
References *36*

3 Chemical Assembly Lines for Skeletally Diverse Indole Alkaloids *43*
Hiroki Oguri
3.1 Introduction *43*
3.2 Macmillan's Collective Total Synthesis by Means of Organocascade Catalysis *45*
3.3 Systematic Synthesis of Indole Alkaloids Employing Cyclopentene Intermediates by the Zhu Group *52*
3.4 Biogenetically Inspired Synthesis Employing a Multipotent Intermediate by the Oguri Group *58*
References *68*

4 Molecular Technology for Injured Brain Regeneration *71*
Itsuki Ajioka
4.1 Introduction *71*
4.2 Biology of Angiogenesis *71*
4.3 Angiogenesis for Injured Brain Regeneration *73*
4.4 Molecular Technology to Promote Angiogenesis *74*
4.5 Biology of Cell Cycle *75*
4.6 Biology of Neurogenesis *77*
4.7 Molecular Technology to Promote Neuron Regeneration *78*
4.8 Conclusion *80*
References *80*

5 Engineering the Ribosomal Translation System to Introduce Non-proteinogenic Amino Acids into Peptides *87*
Takayuki Katoh
5.1 Introduction *87*
5.2 Decoding the Genetic Code *88*
5.3 Aminoacylation of tRNA by Aminoacyl-tRNA Synthetases *90*
5.4 Methods for Preparing Noncanonical Aminoacyl-tRNAs *91*
5.4.1 Ligation of Aminoacyl-pdCpA Dinucleotide with tRNA Lacking the 3′-Terminal CA *91*
5.4.2 Post-aminoacylation Modification of Aminoacyl-tRNA *93*
5.4.3 Misacylation of Non-proteinogenic Amino Acids by ARSs *94*
5.4.4 Flexizyme, an Aminoacylation Ribozyme *94*
5.5 Methods for Assigning Non-proteinogenic Amino Acids to the Genetic Code *95*
5.5.1 The Nonsense Codon Method *96*
5.5.2 Genetic Code Reprogramming *97*
5.5.3 The Four-base Codon Method *98*
5.5.4 The Nonstandard Base Method *100*
5.6 Limitation of the Incorporation of Noncanonical Amino Acids: Substrate Scope *101*

5.7 Improvement of the Substrate Tolerance of Ribosomal Translation *103*
5.8 Ribosomally Synthesized Noncanonical Peptides as Drug Discovery Platforms *104*
5.9 Summary and Outlook *105*
References *106*

6 Development of Functional Nanoparticles and Their Systems Capable of Accumulating to Tumors *113*
Satoru Karasawa
6.1 Introduction *113*
6.2 Accumulation Based on Aberrant Morphology and Size *114*
6.3 Accumulation Based on Aberrant pH Microenvironment *117*
6.4 Accumulation Based on Temperature of Tumor Microenvironment *124*
6.5 Perspective *129*
References *129*

7 Glycan Molecular Technology for Highly Selective *In Vivo* Recognition *131*
Katsunori Tanaka
7.1 Molecular Technology for Chemical Glycan Conjugation *133*
7.1.1 Conjugation to Lysine *133*
7.1.2 Conjugation to Cysteine *133*
7.1.3 Bioorthogonal Conjugation *136*
7.1.4 Enzymatic Glycosylation *136*
7.2 *In Vivo* Kinetic Studies of Monosaccharide-Modified Proteins *137*
7.2.1 Dissection-Based Kinetic and Biodistribution Studies: Effects of Protein Modification by Galactose, Mannose, and Fucose *137*
7.2.2 Noninvasive Imaging of *In Vivo* Kinetic and Organ-Specific Accumulation of Monosaccharide-Modified Proteins *138*
7.3 *In Vivo* Kinetic Studies of Oligosaccharide-Modified Proteins *139*
7.3.1 *In Vivo* Kinetics of Proteins Modified by a Few Molecules of *N*-glycans *139*
7.3.2 *In Vivo* Kinetics of Proteins Modified by Many *N*-glycans: Homogeneous *N*-glycoalbumins *141*
7.3.3 *In Vivo* Kinetics of Proteins Modified by Many *N*-glycans: Heterogeneous *N*-glycoalbumins *145*
7.3.4 Tumor Targeting by *N*-glycoalbumins *148*
7.3.5 Glycan Molecular Technology on Live Cells: Tumor Targeting by *N*-glycan-Engineered Lymphocytes *148*
7.4 Glycan Molecular Technology Adapted as Metal Carriers: *In Vivo* Metal-Catalyzed Reactions within Live Animals *150*
7.5 Concluding Remarks *153*
Acknowledgments *155*
References *155*

8 Molecular Technology Toward Expansion of Nucleic Acid Functionality *165*
Michiko Kimoto and Kiyohiko Kawai
8.1 Introduction *165*
8.2 Molecular Technologies that Enable Genetic Alphabet Expansion *168*
8.2.1 Nucleotide Modification *168*
8.2.2 Unnatural Base Pairs (UBPs) as Third Base Pairs Toward Expansion of Nucleic Acid Functionality *168*
8.2.3 High-Affinity DNA Aptamer Generation Using the Expanded Genetic Alphabet *169*
8.3 Molecular Technologies that Enable Fluorescence Blinking Control *171*
8.3.1 Single Molecule Detection Based on Blinking Observations *171*
8.3.2 Blinking Kinetics *172*
8.3.3 Control of Fluorescence Blinking by DNA Structure *174*
8.3.3.1 Triplet Blinking *174*
8.3.3.2 Redox Blinking *175*
8.3.3.3 Isomerization Blinking *176*
8.4 Conclusions *178*
Acknowledgments *178*
References *178*

9 Molecular Technology for Membrane Functionalization *183*
Michio Murakoshi and Takahiro Muraoka
9.1 Introduction *183*
9.2 Synthetic Approach for Membrane Functionalization *185*
9.2.1 Formation of Multipass Transmembrane Structure *185*
9.2.2 Formation of Supramolecular Ion Channels *187*
9.2.3 Demonstration of Ligand-Gated Ion Transportation *187*
9.2.4 Light-Triggered Membrane Budding *190*
9.3 Semi-biological Approach for Membrane Functionalization *191*
9.3.1 Mechanical Analysis of the Transmembrane Structure of Membrane Proteins *191*
9.3.2 Development of the Nanobiodevice Using a Membrane Protein Expressing in the Inner Ear *193*
9.3.3 Improvement of Protein Performance by Genetic Engineering *198*
References *199*

10 Molecular Technology for Degradable Synthetic Hydrogels for Biomaterials *203*
Hiroharu Ajiro and Takamasa Sakai
Scope of the Chapter *203*
10.1 Degradation Behavior of Hydrogels *203*
10.2 Polylactide Copolymer *205*
10.3 Trimethylene Carbonate Derivatives *207*
10.4 Polyurethane *211*
References *213*

11 Molecular Technology for Epigenetics Toward Drug Discovery *219*
Takayoshi Suzuki
11.1 Introduction *219*
11.2 Epigenetics *219*
11.3 Isozyme-Selective Histone Deacetylase (HDAC) Inhibitors *221*
11.3.1 Identification of HDAC3-Selective Inhibitors by Click Chemistry Approach *221*
11.3.2 Identification of HDAC8-Selective Inhibitors by Click Chemistry Approach and Structure-Based Drug Design *224*
11.3.3 Identification of HDAC6-Insensitive Inhibitors Using C–H Activation Reaction *224*
11.3.4 Identification of HDAC6-Selective Inhibitors by Substrate-Based Drug Design *228*
11.3.5 Identification of SIRT1-Selective Inhibitors by Target-Guided Synthesis *228*
11.3.6 Identification of SIRT2-Selective Inhibitors by Structure-Based Drug Design and Click Chemistry Approach *232*
11.4 Histone Lysine Demethylase (KDM) Inhibitors *234*
11.4.1 Identification of KDM4C Inhibitors by Structure-Based Drug Design *235*
11.4.2 Identification of KDM5A Inhibitors by Structure-Based Drug Design *237*
11.4.3 Identification of KDM7B Inhibitors by Structure-Based Drug Design *238*
11.4.4 Identification of LSD1 Inhibitors by Target-Guided Synthesis *239*
11.4.5 Small-Molecule-Based Drug Delivery System Using LSD1 and its Inhibitor *250*
11.5 Summary *253*
References *254*

12 Molecular Technology for Highly Efficient Gene Silencing: DNA/RNA Heteroduplex Oligonucleotides *257*
Kotaro Yoshioka, Kazutaka Nishina, Tetsuya Nagata, and Takanori Yokota
12.1 Introduction *257*
12.2 Therapeutic Oligonucleotides *257*
12.2.1 siRNA *257*
12.2.2 ASO *258*
12.3 Chemical Modifications of Therapeutic Oligonucleotide *259*
12.3.1 Modifications of Internucleotide Linkage *259*
12.3.2 Modifications of Sugar Moiety *260*
12.4 Ligand Conjugation for DDS *261*
12.4.1 Development of Ligand Molecules for Therapeutic Oligonucleotides *261*
12.4.2 Vitamin E for Ligand Molecule *261*
12.4.3 siRNA Conjugated with Tocopherol *261*
12.4.4 ASO Conjugated with Tocopherol *261*
12.5 DNA/RNA Heteroduplex Oligonucleotide *262*

12.5.1 Basic Concept of Heteroduplex Oligonucleotide *262*
12.5.2 HDO Conjugated with Tocopherol (Toc-HDO) *264*
12.5.2.1 Design of Toc-HDO *264*
12.5.2.2 Potency of Toc-HDO *264*
12.5.2.3 Adverse Effect of Toc-HDO *266*
12.5.2.4 Mechanism of Toc-HDO *268*
12.6 Future Prospects *269*
References *269*

13 Molecular Technology for Highly Sensitive Biomolecular Analysis: Hyperpolarized NMR/MRI Probes *273*
Shinsuke Sando and Hiroshi Nonaka
13.1 Hyperpolarization *273*
13.2 Requirements for HP Molecular Imaging Probes *275*
13.3 HP ^{13}C Molecular Probes for Analysis of Enzymatic Activity *277*
13.3.1 [1-^{13}C]Pyruvate *277*
13.3.2 HP ^{13}C Probes for Analysis of Glycolysis and Tricarboxylic Acid Cycle *278*
13.3.3 γ-Glutamyl-[1-^{13}C]glycine: HP ^{13}C Probe for Analysis of γ-glutamyl Transpeptidase *278*
13.3.4 [1-^{13}C]Alanine-NH_2: HP ^{13}C Probes for Analysis of Aminopeptidase N *282*
13.4 HP ^{13}C Molecular Probes for Analysis of the Chemical Environment *283*
13.4.1 [1-^{13}C]Bicarbonate *283*
13.4.2 [1-^{13}C]Ascorbate and Dehydroascorbate *283*
13.4.3 [^{13}C]Benzoylformic Acid for Sensing H_2O_2 *284*
13.4.4 [^{13}C,D_3]-*p*-Anisidine for Sensing of HOCl *284*
13.4.5 [^{13}C,D]EDTA for Sensing of Metal Ions *285*
13.5 HP ^{15}N Molecular Probes *286*
13.6 A Strategy for Designing HP Molecular Probes *287*
13.6.1 Scaffold Structure for Design of ^{15}N HP Probes: [^{15}N,D_9]TMPA *288*
13.6.1.1 [^{15}N,D_{14}]TMPA *291*
13.6.2 Scaffold Structure for Designing ^{13}C Hyperpolarized Probes *292*
13.7 Conclusion *294*
References *294*

14 Molecular Technologies in Life Innovation: Novel Molecular Technologies for Labeling and Functional Control of Proteins Under Live Cell Conditions *297*
Itaru Hamachi, Shigeki Kiyonaka, Tomonori Tamura, and Ryou Kubota
14.1 General Introduction *297*
14.2 Ligand-Directed Chemistry for Neurotransmitter Receptor Proteins Under Live Cell Condition and its Application *300*
14.3 Affinity-Guided DMAP Reaction for Analysis of Live Cell Surface Proteins *308*
14.4 Coordination Chemistry-Based Chemogenetic Approach to Switch the Activity of Glutamate Receptors in Live Cells *312*
14.5 Concluding Remarks *320*
References *321*

15 Molecular Technologies for Pseudo-natural Peptide Synthesis and Discovery of Bioactive Compounds Against Undruggable Targets *329*
Joseph M. Rogers and Hiroaki Suga
15.1 Introduction *329*
15.2 Peptides Could Target Undruggable Targets *330*
15.2.1 Druggable Proteins *330*
15.2.2 Undruggable Proteins *332*
15.2.3 Natural Peptides as Drugs *333*
15.2.4 Modification to Peptides can Improve Their Drug-Like Characteristics *334*
15.2.4.1 Macrocyclization *334*
15.2.4.2 Amino Acids with Unnatural Side Chains *335*
15.2.4.3 Backbone Modifications Including N-Methylation *335*
15.2.4.4 Cyclosporin – A Membrane-Permeable Anomaly *336*
15.2.4.5 Membrane Permeability Cannot be Calculated from Amino Acid Content *336*
15.2.5 Cyclosporin – The Inspiration for the Cyclic Peptide Approach to Undruggable Targets *337*
15.3 Molecular Technologies to Discover Functional Peptides *337*
15.3.1 Ribosomal Synthesis of Peptides *337*
15.3.2 Natural Peptide Synthesis is an Efficient Method to Generate Huge Libraries *339*
15.3.3 Selection Methods *340*
15.3.3.1 Intracellular Peptide Selection *340*
15.3.3.2 Phage Display *341*
15.3.3.3 A Cell-Free Display, mRNA Display *345*
15.3.4 Other Methods of Selection *347*
15.4 Molecular Technology for Pseudo-natural Peptide Synthesis and Its Use in Peptide Drug Discovery *347*
15.4.1 The Need for Pseudo-natural Synthesis – The Limitations of SPPS *348*
15.4.2 Intein Cyclization and SICLOPPS *348*
15.4.3 Post-translation Modification *351*
15.4.4 Genetic Code Expansion *352*
15.4.5 Replacing Amino Acids in Translation *354*
15.4.6 Genetic Code Reprogramming *355*
15.4.6.1 Flexizymes *355*
15.4.6.2 RaPID System *356*
15.5 Conclusion *361*
Acknowledgment *361*
References *362*

Index *371*